Back to top
more

Accuray (ARAY)

(Delayed Data from NSDQ)

$1.91 USD

1.91
684,092

+0.14 (7.91%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $1.92 +0.01 (0.52%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Here's Why You Should Invest in Intuitive Surgical Stock Now

Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base. However, stiff competition remains a woe.

Here's Why You Should Hold on to OPKO Health Stock for Now

OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.

Allscripts (MDRX) Q4 Earnings and Revenues Miss Estimates

Allscripts (MDRX) fourth-quarter results gain from higher revenues along with growth in bookings. Contraction in both gross and operating margins remains a woe.

Veeva Systems (VEEV) Q4 Earnings and Revenues Beat Estimates

Veeva Systems (VEEV) gains from segmental strength in the fiscal fourth quarter.

Here's Why You Should Hold Avanos Medical (AVNS) Stock Now

Avanos (AVNS) gains from solid fourth-quarter show despite headwinds in the Acute Pain business.

What's in Store for Cooper Companies (COO) Q1 Earnings?

Cooper Companies (COO) fiscal first-quarter performance is likely to reflect better-than-expected performance at CVI and CSI, and higher revenues.

Here's Why You Should Invest in Integer Holdings Stock Now

Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.

DENTSPLY SIRONA (XRAY) Q4 Earnings Lag Estimates, Sales Rise

DENTSPLY SIRONA (XRAY) gains from the Technologies & Equipment arm in Q4.

Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates

Glaukos (GKOS) fourth-quarter results benefit from revenue growth. However, rise in operating expenses remains a concern.

Why Is Accuray (ARAY) Down 28.2% Since Last Earnings Report?

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Avanos (AVNS) Earnings and Revenues Beat Estimates in Q4

Avanos (AVNS) gains from segmental contributions in Q4.

OPKO Health (OPK) Q4 Loss Narrower Than Estimates, Sales Up

OPKO (OPK) gains from increase in RAYALDEE prescriptions.

LHC Group (LHCG) Q4 Earnings Meet Estimates, Revenues Lag

LHC Group (LHCG) fourth-quarter results benefit from home health and hospice admissions and higher revenues.

Patterson Companies (PDCO) Q3 Earnings Top Estimates, Up Y/Y

Patterson Companies' (PDCO) fiscal third-quarter results benefit from higher revenues and solid show by Dental as well as Animal Health segments.

Nevro (NVRO) Q4 Loss Narrower Than Expected, Revenues Up Y/Y

Nevro (NVRO) sees strong segmental contributions in Q4.

Orthofix (OFIX) Q4 Earnings Match Estimates, Margins Decline

We are upbeat about the year-over-year revenue growth recorded by majority of Orthofix's (OFIX) key operating segments in Q4.

Inogen's (INGN) Q4 Earnings Miss, Revenues Top Estimates

Inogen (INGN) sees segmental softness in the fourth quarter.

Penumbra (PEN) Q4 Earnings Beat Estimates, Margins Expand

Penumbra (PEN) registers balanced segmental growth across all geographies in Q4.

Merit Medical (MMSI) Q4 Earnings & Revenues Beat Estimates

Merit Medical's (MMSI) fourth-quarter results gain from higher revenues and solid segmental performance benefit. However, contraction in gross margin remains a concern.

PRA Health (PRAH) Q4 Earnings and Revenues Beat Estimates

Solid Clinical Research revenues drove PRA Health's (PRAH) Q4 results.

HMS Holdings (HMSY) Q4 Earnings and Revenues Miss Estimates

HMS Holdings' (HMSY) fourth-quarter earnings benefit from higher revenues at Analytical Services unit and strong 2020 outlook.

Fresenius Medical (FMS) Q4 Earnings Beat Estimates, Up Y/Y

Fresenius Medical's (FMS) fourth-quarter earnings benefit from strong segmental performance and solid 2020 EPS outlook.

Integer Holdings (ITGR) Q4 Earnings & Revenues Top Estimates

Integer Holdings' (ITGR) fourth-quarter earnings benefit from higher revenues and strong segmental performance.

Masimo (MASI) Q4 Earnings Beat Estimates, View Impressive

Masimo (MASI) sees expansion in gross and operating margin in Q4.

Syneos Health (SYNH) Tops Q4 Earnings and Revenue Estimates

We are upbeat about the strong year-over-year revenue growth in the Clinical Solutions segment of Syneos Health (SYNH) in Q4.